Switch to Karen Gelmon's research page...

2007

1. Campbell KL, Lane K, Martin AD, Gelmon KA, McKenzie DC. Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer. Cancer Nurs. 30(2):95-100. (2007).
    [View Abstract - PubMed 17413774]  Request Paper

2. Gelmon K. Prescribing extended adjuvant letrozole. Breast. . (2007).
    [View Abstract - PubMed 17544670]  Request Paper

3. Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, Gelmon KA. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol. 18(1):45-51. Epub 2006 Oct 9. (2007).
    [View Abstract - PubMed 17030545]  Request Paper

4. Mackey John and Gelmon Karen. Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications. Current Opinion in Oncology. 19(supp 1):S9-18. (2007).
    Request Paper

5. Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res. 13(4):1238-45. (2007).
    [View Abstract - PubMed 17317835]  Request Paper

6. Pansegrau GK, Grant DR, Norris B, Gelmon KA. Trastuzumab-associated peripheral vascular toxicity. J Clin Oncol. 25(11):1438-40. (2007).
    [View Abstract - PubMed 17416865]  Request Paper

7. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 369(9555):29-36. (2007).
    [View Abstract - PubMed 17208639]  Request Paper

2006

8. Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 24(36):5637-44. Epub 2006 Nov 20. (2006).
    [View Abstract - PubMed 17116944]  Request Paper

9. Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 24(18):2773-8. Epub 2006 May 8. (2006).
    [View Abstract - PubMed 16682726]  Request Paper

10. Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist. 11 Suppl 1:42-51. (2006).
     [View Abstract - PubMed 16971739]  Request Paper

11. Kennecke HF, Ellard S, O'Reilly S, Gelmon KA. New guidelines for treatment of early hormone positive breast cancer with tamoxifenand aromatase inhibitors. BCMJ. 48:121-6 (2006).
     Request Paper

12. Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 24(30):4888-94. Epub 2006 Oct 2. (2006).
     [View Abstract - PubMed 17015884]  Request Paper

13. Robinson AG, Turbin D, Thomson T, Yorida E, Ellard S, Bajdik C, Huntsman D, Gelmon K. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer. 7(3):254-61. (2006).
     [View Abstract - PubMed 16942643]  Request Paper

14. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66(1):393-403. (2006).
     [View Abstract - PubMed 16397254]  Request Paper

15. Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol. 19(1):69-74. (2006).
     [View Abstract - PubMed 16258514]  Request Paper

16. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).
     [View Abstract - PubMed 17017873]  Request Paper

2005

17. Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, Gelmon KA. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 23(4):311-5. (2005).
     [View Abstract - PubMed 16012790]  Request Paper

18. Chia S, Bryce C, Gelmon K. The 2000 EBCTCG overview: a widening gap. Lancet. 365(9472):1665-6. (2005).
     [View Abstract - PubMed 15894082]  Request Paper

19. Gelmon KA, Belanger K, Soulieres D, Britten C, Chia S, Charpentier D, Chi K, Powers J, Walsh W, Seymour L. A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130. Invest New Drugs. 23(5):445-53. (2005).
     [View Abstract - PubMed 16133796]  Request Paper

20. Martin M, Pienkowski MD, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C for the Breast International Research Group 001 Investigators . Adjuvant Docetaxel for Node Positive Breast Cancer. NEJM. 352:2302-13. (2005).
     Request Paper

21. McCullum M, Bottoroff JL, Balneaves LG, Davison BJ, Esplen MJ, Kim-Sing C, Gelmon KA, Lamb S, Kuusk U, Kieffer S. Tough choices: A preliminary evaluation of an intervention to support decision making about prophylactic mastectomy. Nursing and Health Sciences. 7:144-5 (2005).
     Request Paper

22. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 23(12):2716-25. (2005).
     [View Abstract - PubMed 15837986]  Request Paper

23. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 97(2):116-26. (2005).
     [View Abstract - PubMed 15657341]  Request Paper

24. Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J, McLeod D, Pritchard K, Provencher L, Verma S. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 6(11):886-98. (2005).
     [View Abstract - PubMed 16257797]  Request Paper

25. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).
     [View Abstract - PubMed 15948035]  Request Paper

26. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103(9):1770-7. (2005).
     [View Abstract - PubMed 15770691]  Request Paper

2004

27. Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, Gelmon K, Chia S, Hayes M. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol. 17(6):690-5. (2004).
     [View Abstract - PubMed 15044916]  Request Paper

28. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res. 2(11):606-19. (2004).
     [View Abstract - PubMed 15561777]  Request Paper

29. Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Hamilton M, Onetto N, Eisenhauer E. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs. 22(3):263-75. (2004).
     [View Abstract - PubMed 15122073]  Request Paper

30. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Klimo P, Schneeweiss A, Bremer K, Soulieres D, Tonkin K, Bell R, Heinrich B, Grenier D, Dias R. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 5(1):52-8; discussion 59-62. (2004).
     [View Abstract - PubMed 15140285]  Request Paper

31. Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. Ann Oncol. 15(7):1115-22. (2004).
     [View Abstract - PubMed 15205207]  Request Paper

32. MacKenzie MJ, Hirte HW, Siu LL, Gelmon K, Ptaszynski M, Fisher B, Eisenhauer E. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol. 15(4):665-70. (2004).
     [View Abstract - PubMed 15033677]  Request Paper

33. Pansegrau GK, Gelmon KA. Lymph-node-negative oestrogen-receptor-positive breast cancer. Lancet. 364(9437):820-1. (2004).
     [View Abstract - PubMed 15351171]  Request Paper

34. Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol. 22(2):269-76. (2004).
     [View Abstract - PubMed 14722035]  Request Paper

35. Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancy J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K, Marx GM, Rutovitz JJ. Phase III study of N, N-diethyl-2 - (4-(Phenylmethyl) Phenoxyl) Etnanamine (BMS-2173802-01) combined with doxorubicin versus doxorubicin alone in metastatic /recurrent breast cancer: National Cancer Institute of Canada Clinical Trial Group Study MA-19. Women's Oncology Review. 4(2):133-4. (2004).
     Request Paper

36. Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, Roskelley CD. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res. 64(15):5068-73. (2004).
     [View Abstract - PubMed 15289306]  Request Paper

37. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res. 10(7):2512-24. (2004).
     [View Abstract - PubMed 15073131]  Request Paper

38. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol Ther. 3(2):197-204. Epub 2004 Feb 1. (2004).
     [View Abstract - PubMed 14726684]  Request Paper

2003

39. Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs. 21(1):85-97. (2003).
     [View Abstract - PubMed 12795533]  Request Paper

40. Gelmon KA, Vandenberg TA, Panasci L, Norris B, Crump M, Douglas L, Walsh W, Matthews SJ, Seymour LK. A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129. Ann Oncol. 14(4):543-8. (2003).
     [View Abstract - PubMed 12649098]  Request Paper

41. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 21(21):3965-71. Epub 2003 Sep 24. (2003).
     [View Abstract - PubMed 14507946]  Request Paper

42. Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol. 3(5):261-71. (2003).
     [View Abstract - PubMed 14696623]  Request Paper

2002

43. De Lemos M. Safety issues of soy phytoestrogens in breast cancer patients. J Clin Oncol. 20(13):3040-1; author reply 3041-2. (2002).
     [View Abstract - PubMed 12089239]  Request Paper

44. Gelmon K, Olivotto I. The mammography screening debate: time to move on. Lancet. 16; 359(9310):909-19. (2002).
     Request Paper

45. Hanna, W and Gelmon K. Review of the literature on Her2/neu testing and the role of Her2/neu as a prognostic and predictive factor in breast cancer - Update December 2000 to July 2001. Current Oncology. 9 supp 1: S2-S17. (2002).
     Request Paper

46. Van Patten CL, Olivotto IA, Chambers GK, Gelmon KA, Hislop TG, Templeton E, Wattie A, Prior JC. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 20(6):1449-55. (2002).
     [View Abstract - PubMed 11896091]  Request Paper

2001

47. Bebb DG, Warrington PJ, de Jong G, Yu Z, Moffat JA, Skov K, Spacey S, Gelmon K, Glickman BW. Radiation induced apoptosis in ataxia telangiectasia homozygote, heterozygote and normal cells. Mutat Res. 476(1-2):13-20. (2001).
     [View Abstract - PubMed 11336979]  Request Paper

48. Gelmon, Karen A and Kim Sing Charmaine. Hormone therapy and breast cancer. BCMJ. 43(9):511-6. (2001).
     Request Paper

49. Leyland-Jones B, Arnold A, Gelmon K, Verma S, Ayoub JP, Seidman A, Dias R, Howell J, Rakhit A. Pharmacologic insights into the future of trastuzumab. Ann Oncol. 12 Suppl 1:S43-7. (2001).
     [View Abstract - PubMed 11521721]  Request Paper

2000

50. Gelmon KA, Latreille J, Tolcher A, Genier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol. 18(24):4098-108. (2000).
     [View Abstract - PubMed 11118471]  Request Paper

1999

51. Bebb DG, Yu Z, Chen J, Telatar M, Gelmon K, Phillips N, Gatti RA, Glickman BW. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br J Cancer. 80(12):1979-81. (1999).
     [View Abstract - PubMed 10471049]  Request Paper

52. Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol. 17(10):3038-47. (1999).
     [View Abstract - PubMed 10506598]  Request Paper

53. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 91(15):1281-7. (1999).
     [View Abstract - PubMed 10433616]  Request Paper

54. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol. 17(2):697-705. (1999).
     [View Abstract - PubMed 10080616]  Request Paper

55. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 17(2):478-84. (1999).
     [View Abstract - PubMed 10080588]  Request Paper

1998

56. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol. 41(5):347-52. (1998).
     [View Abstract - PubMed 9523729]  Request Paper

57. Gelmon K, Tolcher A, O'Reilly S, Shenkier T. A phase II study of biweekly paclitaxel in metastatic breast cancer. Annals of Oncology. 9: 1247-9. (1998).
     Request Paper

58. Gelmon KA. The fine points of endpoints. Phase II trials in non small cell lung cancer. Annals of Oncol. 9:1045-6 (1998).
     Request Paper

59. Latreille J, Gelmon KA, Hirsh V, Laberge F, Maksymiuk AW, Shepherd FA, Delorme F, Berille J. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest New Drugs. 16(3):265-70. (1998).
     [View Abstract - PubMed 10360607]  Request Paper

60. Murray N, Grafton C, Shah A, Gelmon K, Kostashuk E, Brown E, Coppin C, Coldman A, Page R. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol. 16(10):3323-8. (1998).
     [View Abstract - PubMed 9779708]  Request Paper

61. O'Reilly S, Shenkier T, Allan S, Gelmon K. Therapy for adjuvant systemic non-cancer Canadian Treatment Guidelines for node positive breast cancer. CMJ 158; (3 Supp). 552-64. (1998).
     Request Paper

62. Shepherd FA, Beaulieu R, Gelmon K, Thuot CA, Sawka C, Read S, Singer J. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol. 16(5):1736-42. (1998).
     [View Abstract - PubMed 9586886]  Request Paper

63. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 42(6):461-70. (1998).
     [View Abstract - PubMed 9788572]  Request Paper

64. Westeel V, Murray N, Gelmon K, Shah A, Sheehan F, McKenzie M, Wong F, Morris J, Grafton C, Tsang V, Goddard K, Murphy K, Parsons C, Amy R, Page R. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol. 16(5):1940-7. (1998).
     [View Abstract - PubMed 9586913]  Request Paper

1997

65. Bebb G, Glickman B, Gelmon K, Gatti R. "AT risk" for breast cancer. Lancet. 349(9068):1784-5. (1997).
     [View Abstract - PubMed 9269208]  Request Paper

66. Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal. 16(4):675-87. (1997).
     [View Abstract - PubMed 9502163]  Request Paper

67. Goss PE, Fine S, Gelmon K, Rudinskas L, Ottaway J, Myles J, James K, Paul K, Rodgers A, Pritchard KI. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chemother Pharmacol. 41(1):53-60. (1997).
     [View Abstract - PubMed 9443614]  Request Paper

68. Kirkbride P, Gelmon K, Eisenhauer E, Fisher B, Dulude H. A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 39(5):1107-11. (1997).
     [View Abstract - PubMed 9392551]  Request Paper

69. Munk PL, Poon PY, O'Connell JX, Janzen D, Coupland D, Kwong JS, Gelmon K, Worsley D. Osteoblastic metastases from breast carcinoma with false-negative bone scan. Skeletal Radiol. 26(7):434-7. (1997).
     [View Abstract - PubMed 9259104]  Request Paper

1996

70. Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, Coppin C, Plenderleith IH, Ayers D, McDermott B, Nakashima L, Healey D, Onetto N. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol. 14(4):1185-91. (1996).
     [View Abstract - PubMed 8648373]  Request Paper

71. Millar JL, Goldstein D, Gelmon KA. Managing HIV. Part 5: Treating secondary outcomes. 5.14 HIV and Kaposi's sarcoma. Med J Aust. 164(9):539-42. (1996).
     [View Abstract - PubMed 8649291]  Request Paper

72. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 14(6):1858-67. (1996).
     [View Abstract - PubMed 8656254]  Request Paper

1995

73. De Jong G, Gelmon K, Bally M, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res. 15(3):911-6. (1995).
     [View Abstract - PubMed 7645981]  Request Paper

1994

74. Arnold A, Ayoub J, Douglas L, Hoogendoorn P, Skingley L, Gelmon K, Hirsh V, Eisenhauer E. Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 86(4):306-9. (1994).
     [View Abstract - PubMed 8158687]  Request Paper

75. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 344(8932):1267-72. (1994).
     [View Abstract - PubMed 7967989]  Request Paper

76. Gelmon K, Member of Concorde Coordinating Committee. MRC/ANRS randomized double-blind controlled total comparing immediate and deferred zidovidine in asymptomatic HIV infection. Lancet. 343(901):892-8. (1994).
     Request Paper

77. Olivotto IA, Bajdik CD, Plenderleith IH, Coppin CM, Gelmon KA, Jackson SM, Ragaz J, Wilson KS, Worth A. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med. 330(12):805-10. (1994).
     [View Abstract - PubMed 8114832]  Request Paper

78. Osoba D, Murray N, Gelmon K, Karsai H, Knowling M, Shah A. Phase II Trial of Megesteriol in the supportive care of patients receiving dose intensive chemotherapy. Oncology. 8(3):43-68. (1994).
     Request Paper

79. Osoba D, Murray N, Gelmon K, Karsai H, Knowling M, Shah A, McLaughlin M, Fetherstonhaugh E, Page R, Bowman CA. Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy. Oncology (Williston Park). 8(4):61-5; discussion 65-6, 69. (1994).
     [View Abstract - PubMed 8003398]  Request Paper

1993

80. Embree L, Gelmon KA, Lohr A, Mayer LD, Coldman AJ, Cullis PR, Palaitis W, Pilkiewicz F, Hudon NJ, Heggie JR, et al.. Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. J Pharm Sci. 82(6):627-34. (1993).
     [View Abstract - PubMed 8392545]  Request Paper

81. Gregg RW, Kaizer L, Fine S, Gelmon K, Wielgosz G, Eisenhauer E. A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group. Ann Oncol. 4(8):693-4. (1993).
     [View Abstract - PubMed 8241002]  Request Paper

82. O'Reilly SE, Gelmon KA, Onetto N, Parente J, Rubinger M, Page RA, Plenderleith IH. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. J Clin Oncol. 11(12):2411-6. (1993).
     [View Abstract - PubMed 8246030]  Request Paper

83. Schechter MT, Craib KJ, Gelmon KA, Montaner JS, Le TN, O'Shaughnessy MV. HIV-1 and the aetiology of AIDS. Lancet. 341(8846):658-9. (1993).
     [View Abstract - PubMed 8095571]  Request Paper

1992

84. Osoba D, Band PR, Goldie JH, Connors JM, Gelmon K, Knowling MA, Fetherstonhaugh EM. Efficacy of weekly cisplatin-based chemotherapy in recurrent and metastatic head and neck cancer. Ann Oncol. 3 Suppl 3:57-62. (1992).
     [View Abstract - PubMed 1390318]  Request Paper

1990

85. Montaner JS, Le T, Fanning M, Gelmon K, Tsoukas C, Falutz J, O'Shaughnessy M, Wainberg MA, Ruedy J. The effect of zidovudine on platelet count in HIV-infected individuals. J Acquir Immune Defic Syndr. 3(6):565-70. (1990).
     [View Abstract - PubMed 2187071]  Request Paper

1989

86. Gelmon K, Weller IV. Randomised placebo controlled trials in HIV infection: to be or not to be? Genitourin Med. 65(3):143-5. (1989).
     [View Abstract - PubMed 2668154]  Request Paper

87. Price LA, Hill BT, Gelmon KA. Intermittent high-dose zidovudine. Lancet. 2(8665):734. (1989).
     [View Abstract - PubMed 2570973]  Request Paper

88. Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao XJ, Fanning M, Montaner JS, O'Shaughnessy M, Gelmon K, Tsoukas C, et al.. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS. 3(7):411-5. (1989).
     [View Abstract - PubMed 2504243]  Request Paper

89. Wainberg MA, Falutz J, Fanning M, Gill J, Gelmon K, Montaner JS, O'Shaughnessy M, Tsoukas C, Ruedy J. Cessation of zidovudine therapy may lead to increased replication of HIV-1. JAMA. 261(6):865-6. (1989).
     [View Abstract - PubMed 2913381]  Request Paper

1997

1. Bebb G, Glickman B, Gelmon K, Gatti R. Lancet 349:1784-1785 (1997).
    Request Paper

2. Kirkbride P, Gelmon K, Eisenhauer E. et al. J of Rad Biol and Phys, 39. 1107-1111 (1997).
    Request Paper

1996

3. Gelmon KA, O'Reilly SE, Tolcher AW, et al. J Clin Oncol, 14: 1185-1191 (1996).
    Request Paper

1994

4. Gelmon K. The Lancet, 344; 1267-72 (1994).
    Request Paper

1993

5. Embree L, Gelmon KA, Lohri A, Mayer LD et al. J. Pharm Sci, 82:627-634 (1993).
    Request Paper

6. O'Reilly S, Gelmon KA, Onetto N et al. J Clin Oncol 11(12) 1-6 (1993).
    Request Paper

1989

7. Gelmon K, Montaner JS, Fanning M et al. AIDS, 3(9); 555-561 (1989).
    Request Paper